At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 479 enrolled
Drug / intervention
ChimeriVax-WN02 vaccine +3 morebiological
Likely dose
Placebo 0.9%from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Modified, Double-blind, Placebo-controlled, Phase II, Dose-ranging Study of the Safety and Immunogenicity of Single Dose ChimeriVax-WN02 Vaccine in Healthy Adults.
In Brief
A Phase 2 clinical trial evaluating ChimeriVax-WN02 vaccine and Placebo for West Nile Fever. Completed, enrolled 479 participants across 15 sites.
Detailed Summary
The purpose of this study is to determine if ChimeriVax West Nile vaccine is safe and effective in preventing West Nile disease in adults over 50 years of age.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWest Nile Fever
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2008
Enrollment StartOct 2008
Primary CompletionJun 2009
Study CompletionDec 2009
TodayJul 2026
First PostedSep 4, 2008
Enrollment StartOct 1, 2008
Primary CompletionJun 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.8 years ago
Interventions
ChimeriVax-WN02 vaccinebiological
low dose, approximately 4 x 3log10, given one time subcutaneously
ChimeriVax-WN02 vaccinebiological
medium dose, approximately 4 x 4log10, given one time
ChimeriVax-WN02 vaccinebiological
high dose, approximately 4 x 5log10, given one time subcutaneously
Placebobiological
0.9%Normal Saline for Injection, given one time subcutaneously